Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity

Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize preclinical studies and the first‐in‐human study of KW‐2450, an oral tyrosine kinase inhibitor with IGF‐1R and insulin receptor (IR) inhibitory activity. Preclinical activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Gary K., Dickson, Mark A., LoRusso, Patricia M., Sausville, Edward A., Maekawa, Yoshimi, Watanabe, Yasuo, Kashima, Naomi, Nakashima, Daisuke, Akinaga, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832855/
https://www.ncbi.nlm.nih.gov/pubmed/26850678
http://dx.doi.org/10.1111/cas.12906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832855/
https://www.ncbi.nlm.nih.gov/pubmed/26850678
http://dx.doi.org/10.1111/cas.12906

Ejemplares similares